Physician profile
Mark A Sibul
NPI 1700841848
$2,846.55
in general payments reported to CMS, 2019-2025
25 companies · $570 in 2025
The $570 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $112 · 2021: $476 · 2022: $242 · 2023: $400 · 2024: $546 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,188.94 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $435.20 | 2020-2025 | Acessa Provu System, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Allergan, INC. | $188.06 | 2019-2020 | |
| Organon LLC | $177.66 | 2023-2025 | Nexplanon |
| Coopersurgical, INC. | $159.96 | 2023-2024 | Endosee, Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $84.59 | 2019-2024 | |
| Exeltis, USA INC. | $72.78 | 2020-2024 | Slynd |
| Vertical Pharmaceuticals, LLC | $66.98 | 2019 | |
| Avion Pharmaceuticals | $52.69 | 2020-2023 | Balcoltra |
| Astellas Pharma US INC | $49.19 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $46.97 | 2020-2025 | |
| Duchesnay USA Incorporated | $44.95 | 2019 | |
| Therapeuticsmd, INC. | $43.61 | 2019 | |
| Radius Health, INC. | $34.93 | 2019 | |
| Ascend Therapeutics US, LLC | $28.33 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $24.42 | 2024 | |
| Exact Sciences Corporation | $24.37 | 2025 | Cologuard Collection Kit |
| Millicent US INC | $20.92 | 2025 | Intrarosa |
| Cytyc Surgical Products, LLC | $18.97 | 2025 | Myosure Tissue Removal Device |
| Evofem Biosciences, INC. | $17.92 | 2021 | |
| Merck Sharp & Dohme LLC | $17.07 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.86 | 2019 | |
| Lupin INC. | $15.64 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sibul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.